CUPERTINO, Calif., May 16, 2019 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX) announced today that James E. Brown, Chief Executive Officer, and
Michael H. Arenberg, Chief Financial
Officer, will be participating in the 20th Annual B.
Riley FBR Institutional Investor Conference, taking place at the
Beverly Hilton Hotel, Beverly Hills,
CA May 22-23.
B. Riley FBR
Institutional Investor Conference
|
|
Presentation
Date:
|
Wednesday, May 22,
2019
|
Presentation
Time:
|
8:30am PDT
|
Location:
|
Beverly Hilton Hotel,
Beverly Hills, CA
|
Webcast:
|
http://www.wsw.com/webcast/brileyfbr3/drrx
|
The live audio webcast of the presentation will also be
available by accessing DURECT's homepage at www.durect.com and
clicking on the "Investors" tab. If you are unable to
participate during the live webcast, the call will be archived on
DURECT's website in the "Event Calendar" of the "Investors"
section.
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR‑928, a new chemical
entity in Phase 2 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally
bioavailable small molecule, DUR-928 has been shown in preclinical
studies to play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may
include acute organ injury such as alcoholic Hepatitis (AH) and
acute kidney injury (AKI), chronic hepatic diseases such as
nonalcoholic steatohepatitis (NASH), and inflammatory skin
conditions such as psoriasis and atopic dermatitis. DURECT's
advanced oral and injectable delivery technologies are designed to
enable new indications and enhanced attributes for small-molecule
and biologic drugs. Late stage product candidates in this
category include POSIMIR® (bupivacaine extended-release
solution), an investigational locally-acting, non-opioid analgesic
intended to provide up to 3 days of continuous pain relief after
surgery, and ORADUR®-Methylphenidate ER Capsules,
approved in Taiwan as Methydur
Sustained Release Capsules, where it is indicated for the treatment
of attention deficit hyperactivity disorder (ADHD). In
addition, for the assignment of certain patent rights, DURECT
receives single digit sales-based earn-out payments from U.S. net
sales of Indivior's PERSERIS™ (risperidone) drug for
schizophrenia, which was commercially launched in February
2019. For more information, please visit www.durect.com.
DURECT Forward-Looking Statement
The statements in this press release regarding the potential use
of DUR-928 to treat chronic hepatic diseases such as NASH, acute
organ injuries such as AH and AKI, and in inflammatory skin
disorders such as psoriasis and atopic dermatitis, the use of
POSIMIR to treat post-surgical pain, the use of Indivior's
PERSERIS™ to treat schizophrenia, as well as the
potential commercial sales of Indivior's PERSERIS are
forward-looking statements involving risks and uncertainties that
can cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
include, but are not limited to, the risk of delays in the
enrollment of the ongoing clinical trials of DUR-928 in NASH, AH
and mild to moderate plaque psoriasis, potential adverse effects
arising from the testing or use of DUR-928, the risk that the FDA
may not approve the POSIMIR NDA, the risk that PERSERIS will not
have a successful launch, our ability to avoid infringing patents
held by other parties and secure and defend patents of our own
patents, and our ability to manage and obtain capital to fund our
operations and expenses. Further information regarding these and
other risks is included in DURECT's Form 10-Q on May 7, 2019 under the heading "Risk Factors."
NOTE: ORADUR™, POSIMIR® and
SABER® are trademarks of DURECT Corporation.
Other referenced trademarks belong to their respective owners.
DUR-928, ORADUR-Methylphenidate ER Capsules and POSIMIR are drug
candidates under development and have not been approved for
commercialization by the U.S. Food and Drug Administration or other
health authorities. For PERSERIS full prescribing information visit
www.perseris.com.
View original
content:http://www.prnewswire.com/news-releases/durect-to-present-at-the-20th-annual-b-riley-fbr-institutional-investor-conference-on-may-22-2019-300852045.html
SOURCE DURECT Corporation